GlassScriptPhysician profile
Micheal Shane Blocker
NPI 1487134052
$2,139.51
in general payments reported to CMS, 2019-2025
31 companies · $879 in 2025
The $879 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $199 · 2022: $283 · 2023: $356 · 2024: $423 · 2025: $879.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $400.10 | 2024-2025 | Airsupra, Farxiga |
| C. R. Bard, INC. & Subsidiaries | $175.61 | 2023-2024 | Bard Urinary Drainage Bag |
| Astellas Pharma US INC | $170.13 | 2021-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.12 | 2024-2025 | Xifaxan |
| Rochester Medical Corporation | $125.63 | 2022 | |
| Glaxosmithkline, LLC. | $111.52 | 2024-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $95.37 | 2021-2025 | Evenity, Prolia, Prolia |
| Corium, LLC | $91.52 | 2025 | Azstarys |
| Myriad Genetic Laboratories, INC. | $75.23 | 2021-2023 | Prolaris |
| Lilly USA, LLC | $68.74 | 2024 | Mounjaro, Jardiance |
| Endo Pharmaceuticals INC. | $64.59 | 2021-2023 | Xiaflex, Edex |
| Axonics, INC. | $62.32 | 2022-2023 | Axonics |
| Bayer Healthcare Pharmaceuticals INC. | $59.23 | 2025 | |
| Pfizer INC. | $56.70 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $52.48 | 2025 | Rexulti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $51.56 | 2021-2025 | Enroute Transcarotid Stent |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.07 | 2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $37.65 | 2025 | Trintellix |
| Allergan, INC. | $24.95 | 2022 | |
| Axsome Therapeutics, INC. | $24.85 | 2025 | Symbravo |
| Teleflex LLC | $24.18 | 2023 | Urolift |
| Janssen Biotech, INC. | $22.74 | 2021 | |
| Progenics Pharmaceuticals, INC. | $20.76 | 2023 | Pylarify |
| Eisai INC. | $20.35 | 2025 | |
| Lundbeck LLC | $19.77 | 2024 | Vyepti |
| Palette Life Sciences, INC. | $19.42 | 2022 | |
| Hologic Sales and Service, LLC | $18.51 | 2024 | Aptima |
| Abbvie INC. | $16.67 | 2023 | |
| Ibsa Pharma INC. | $15.03 | 2025 | Tirosint, Licart, Flector |
| Novo Nordisk INC | $14.72 | 2025 | Ozempic |
| Myovant Sciences INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Micheal Blocker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.